AdvaMed Code of Ethics on Interactions with Health Care Professionals in China

Stephanie Chew

Head, Ethics and Compliance Medtronic Greater China



13 September 2017





About the Speaker

Stephanie Chew

Head of Ethics and Compliance, Greater China Medtronic

Disclaimer:

Stephanie Chew is speaking on behalf of AdvaMed. All information and ideas expressed by the individual DOES NOT represent the view of Medtronic.

The Speaker makes no warranty or representation in relation to content or accuracy of the material presented. The Speaker expressly disclaims any and all liability (including liability for negligence) in respect of use of the information provided.

The Speaker recommends you seek independent professional advice prior to making any decision involving matters outlined in this presentation or meeting.






Agenda







Agenda





Who is AdvaMed?





Advanced Medical Technology Association (AdvaMed)

- World's largest medical technology association
- •Nearly 300 members with a global presence in countries including China, Europe, India, Brazil and Japan
- •Advocate on a global basis for the highest ethical standards, timely patient access to safe and effective products and economic policies that reward value recreation
- •Act as the common voice for companies producing medical devices, diagnostic products and health information systems









AdvaMed Member Companies in China





Ortho Clinical Diagnostics































Agenda





Corruption and Bribery: Headline News

THE ECONOMIC TIMES

Siemens, Philips, GE medical devices units face bribery probe in China

COMPLIANCE WEEK

THE LEADING INFORMATION SERVICE ON CORPORATE GOVERNANCE, RISK, AND COMPLIANCE

China Targets Medical Device Companies in Bribery Probe



SEC Charges Medical Device Company Biomet with Foreign Bribery



AstraZeneca to pay \$5.52 million to resolve SEC foreign bribery case

THE WALL STREET JOURNAL.

Medical Device Company Settles Foreign Bribery Charges

sina新浪财经

近四百名医生倒在医疗反腐风暴中 医用耗材成腐败新高

中国医疗器被


搜 狐 SeHU.com 涉嫌行贿,美敦力代理经销商、医械公司老总等被抓!(还有大量医院科室主任落马)

医械行业反腐重锤,纪委介入采购全过程!

2017-04-27 09:07









China Enforcement Overview

- Enforcement hot spot for U.S. authorities
- Recent settlements show need for adequate internal controls and timely disclosure of misconduct
- China's domestic anti-corruption campaign continues, including scrutiny of health care industry
 - Major healthcare cases may be jointly handled by several ministries/agencies
 - Local Administration of Industry and Commerce (AIC)
 continue to target commercial bribery in health care sector
 - Local AIC have broadened scope of misconduct considered commercial bribery
 - New draft amendments to the Anti-Unfair Competition Law ("AUCL") could reshape the commercial bribery scheme, including more precisely defining commercial bribery, expanding the scope of liability, and heftier fines





Corruption Criminal Investigations

2016 Corruption Criminal Investigations in Device Industry

- People's Procuratorate publicized at least 32 criminal bribery actions against medical device companies
 - Companies and individuals were penalized
 - Largest number of implicated institutions were in Jiangsu and Henan provinces
 - Orthopedics departments and clinical laboratories were most often implicated
- Over 386 HCPs, including well-known directorchiefs of hospitals or hospital departments, were brought down in criminal corruption investigations










Looking Ahead

- National Health and Family Planning Commission (NHFPC) announced inspections of 85 third-grade class-A hospitals for potential corruption and compliance problems in 2017
- Trends indicate bribery crackdown in health care sector (including the device industry) will continue, especially with respect to the purchase of consumables









Agenda







AdvaMed China Code



- AdvaMed Code of Ethics on Interactions with Health Care Professionals in China (AdvaMed China Code)
- Adopted March 2015; Effective 1 January 2016)
- Jointly signed by China Association for Medical Devices Industry (CAMDI) in October 2016
- Goals & Background:
 - Industry self-regulatory approach designed to proactively address potential antibribery/anti-corruption concerns in the Chinese marketplace
 - Derived from best practices and global compliance trends
 - Establishes baseline compliance guidelines for companies to incorporate into their policies on customer and HCP interactions
 - Serves as a foundational document for medical device industry in China
 - Helps ensure collaborative, necessary relationships between device companies and HCPs meet high ethical standards
 - Conducted with transparency and in compliance with laws







- Addresses critical topics:
 - Company-Conducted Product Training and Education
 - Supporting Third-Party Educational Conferences
 - Sales, Promotional, and Other **Business Meetings**
 - Consulting Arrangements with HCPs
 - Prohibition on Entertainment & Recreation
 - Modest Meals & Travel Associated with HCP **Business Interactions**
 - Educational & Branded Promotional Items
 - Research, Academic and Public Education **Grants**; Charitable Donations
 - **Evaluation and Demonstration Products**
 - Third Party Sales and Marketing Intermediary ("SMI") Relationships



- Preamble: Goal and Scope of AdvaMed China Code
- develop, produce, manufacture, and market medical products, technologies and related ervices and therapies used to diagnose, treat, monitor, manage and alleviate health anditions and disabilities ("Medical Technologies") in order to enable patients to live longer and healthier lives (collectively "Companies," and individually "Company") AdvaMed is dedicated to the advancement of medical science, the improvement of patient care, and, in particular, the contributions that high quality, innovative Medical Technologies make toward achieving these goals.
- The China Board recognizes the obligation to facilitate ethical interactions between Companies and institutions involved in the provision of health care services and/or tems to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Companies' Medical Technologies in the People's Republic of China ("institutional Health Care Professionals") as well as the individuals employed by these institutions (and who are not full-time employees of a Company) who are also involved in the provision of health care services and/or items to patients and who also purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Companies' Medical Technologies ("individual Health Care Professionals"). Unless otherwise specified, the term "Health Care Professionals" refers to individuals and

Medical Technologies are often highly dependent upon "hands on" Health Care Professional interaction from beginning to end—unlike drugs and biologics, which act on the human body by pharmacological, immunological or metabolic means. For example, implantable Medical Technologies are often placed in the human body to replace or strengthen a body part. Surgical Medical Technologies often serve as extensions of a physician's hands. In other circumstances, Medical Technologies are noninvasive reagents, instrumentation and/or software to aid in the diagnosis, monitoring and treatment decisions made by Health Care Professionals. Some Medical Technologies





与中国医疗卫生专业人士互动交流的道德规范 被美国朱泽族的技术协会中国非常企业协 2016年1月1日生産

- 1. 果国生进程疗技术协会 ("协会") 代表了从事开发、写声、制造和被有程疗产品、技术和和工 相条为由作为法("张疗性术")等会条的公司。州州州的会条用于边断、处理、监控、管理 和理解起来问题与身体疾患。以其私患者的寿命并改善患者的秘密。协会放力于促进抵乎发展。 改善思考疑事。特别是通过贡献高质量、但新医疗技术来实现这些目标。
- 2. 协会中国理事企业协会在中国设定的理事机构、由协会成员公司在中国的最高级制的管理人员
- 的个人(包括成员公司的专全职员工)合理的发动交流合作为记任。这些机构在中华人民共和国 购买、租赁、售费、使用、安排采购或租用、或者处为使用公司的医疗技术、移为 "医疗机 约"。这些机构所是自的人类(包括业业职人类)也参与为要者提供医疗保健报告和"成物品 以发购买、租赁、售券、使用、安排采购或租用。或者处方使用公司的医疗效果、释为"医疗 卫生专业人士"、除业特别证明、古初"医疗卫生专业人士"包括了上述个人和机构。

医疗性术者常高度结核干压疗卫生专业人士从外来产品参加。不像药品和生物制品系统过 药物、免疫或酶品代谢等力式作用于人体、例如、可能人物品疗性术者常用于更换成加强人 体特定报行、并构运疗技术通常用于扩展医效双手的功能。在其它时候,医疗技术为申使人 式试剂、仅每和"成款件、用于整职银行工生专业人士作品设备、监狱和处理决定。一些银行 性术可以与其它性术协同使用。或者与其它产品配合、通过最安全和有效的方式操作这些证 备。许多医疗技术应接作期间和操作后都需要技术文件。

1. NECTSTRALIBRAÇÃ

据疗卫生专业人士与公司的有益发动交流是属非常广泛、工管由于加下目的

A. 加强运行技术使用的安全性和有效性、为了安全、有效地使用精密电子、体料设施、机 科威其它医疗技术。 通常要求会司为医疗习生专业人士提供适当的指导。教育和培训。 监管机构建筑可此来所谓作为规准产品的打提条件。

SINGE CONSTRUCTION OF THE PROPERTY OF THE PROP

Includes FAQs that provide additional details to assist companies in implementation and decision-making








Companies may make training and education on products and medical technologies available to HCPs

•Including:

- Hands-on training sessions
- Cadaver workshops
- Lectures and presentations



Principles for conducting training and education programs:

- Conducted in settings that are conducive to the effective transmission of information
- Held in appropriate facilities
- May provide HCPs with modest meals/refreshments
- May pay for reasonable travel and modest lodging of the attending HCP







Companies may conduct sales, promotional and other business meetings with HCPs:

•Purpose:

To discuss medical technology features, sales terms, or contracts

•Location:

- Most commonly occur close to the HCP's place of business
- Can occur in other cities within China or overseas

•Expenses:

- May pay for reasonable travel costs of attendees
- May <u>not</u> pay any expenses of guests of HCPs
- May <u>not</u> pay any expenses of any other person who does not have a *bona fide* professional interest in the information at the meeting







Companies may pay HCP consultants for bona fide consulting services

- Examples: contracts for research; product development; development and/or transfer of intellectual property; participation on advisory boards; conducting technical training on products
- Must pay fair market value
- Must fulfill a legitimate business need
- Must not constitute an unlawful inducement



Must:

- Be in writing, and describe all services to be provided
- Be entered into <u>only</u> where a legitimate need for the services is identified in advance and documented
- Be based on the consultant's qualifications and expertise to meet the desired need
- Include compensation consistent with the fair market value in an arm's length transaction
- Include a written research protocol where necessary



Must NOT:

- Involve HCPs selected, controlled, or influenced by sales personnel
- Be based on the consultant's value or business volume
- Be paid in cash








Companies may <u>not</u> provide or pay for any entertainment or recreational event or activity for any HCP

OAll company interactions with HCPs should facilitate the exchange of medical or scientific information that will benefit patient care

Examples of prohibited activities:

- Theater
- Sporting events
- Lavish meals
- Leisure or vacation trips



Such events and activities should not be provided regardless of:

- Value
- Whether HCP is engaged as a speaker or consultant
- Whether the entertainment or recreation value is secondary to an educational purpose







Companies may provide modest meals as an occasional business courtesy

•Purpose:

- Incidental and conducive to a bona fide presentation of scientific, educational or business information
- Not part of an entertainment or recreational event

•Setting & Location:

- At HCP's place of business, unless impractical or inappropriate:
 - Where medical technology cannot easily be transported to HCP's location
 - When it is necessary to discuss confidential product development or improvement information
 - · Where a private space cannot be obtained on-site

•Guidelines for appropriate participants at meals:

- Only those HCPs who actually attend the associated meeting
- Only when a Company representative is present
- Not provided to an entire office staff (where everyone does not attend meeting)
- Not provided to guests of HCPs
- Not provided to any person who does not have a bona fide professional interest in the information shared at the meeting







Companies may provide reasonable travel expenses for individual HCPs

•Purpose:

- Bona fide scientific, educational, or business purpose for HCP travel
- Length of trip commensurate with purpose
- No recreational activities, side trips, city tours, or other activities that do not support bona fide professional purpose



<u>Location</u>:

- Adopt objective criteria to select locations and venues
- Consider local alternatives before sponsoring travel for HCPs
- Consider China-based alternatives before sponsoring international travel for HCPs

Reasonable Expenses:

- Flights
- Hotels
- Meals
- Incidentals

Reimbursement:

- Pay airlines and hotels directly if possible / practical
- No cash reimbursement for expenses > RMB 500

Participants:

- No reimbursement to guests of HCPs
- Reimbursement only to persons with a bona fide professional interest in the activity requiring travel



Companies may occasionally provide HCPs with items that benefit patients or

serve a genuine educational function

•Should be of modest, fair-market value, with two exceptions:

- Medical textbooks
- Anatomical models used for educational purposes

Branded Promotional Items

- Should be of minimal value, ≤ RMB 200
- Ex: stationery items; USB drives; mouse pads; other items bearing the company's logo

Prohibited items:

- Any items banned by local law
- Items capable of use for non-educational or non-patient-related purposes, such as smartphones, tablet computers, laptops
- Alcohol
- Tobacco
- Cash, gift cards, or other cash equivalents









Companies may provide research & educational grants and charitable donations to HCPs

•Grants/donations may not be provided as an unlawful inducement:

- Adopt objective criteria, and implement procedures to ensure compliance
 - Criteria should <u>not</u> include sales considerations (e.g., volume of business from the recipient)
- Fully document all grants and donations
- Companies should not control or unduly influence who receives grants/donations, or the amount awarded

•Impose requirements on the grant or donation:

- Must be accepted by the legal institutional entity
 - Not internal departments
 - Not individual HCPs
- Should be handled by the institution's financial department
- Used for bona fide non-profit activities
- Not conditioned on buying products/services, or other factors affecting fair competition







Companies may provide reasonable quantities of no-charge products to institutions for evaluation and demonstration purposes

- Allows HCPs to assess appropriate use and functionality of product, to determine future need
- Must <u>not</u> be conditioned on buying products or services, or otherwise affect fair competition

<u>Single Use / Consumables / Disposables</u>:

- Provide no greater amount than necessary for product evaluation
- Terms of no-charge status and evaluation to be disclosed in writing to the HCP
- Make any additional disclosures required by local

Multiple Use / Capital Equipment:

- May be provided for a reasonable period of time to allow evaluation
- Terms of evaluation to be disclosed in writing to the institution (<u>not</u> internal departments; <u>not</u> individual HCPs)
- Company retains title to product during eval period
- Promptly remove product at end of eval period, unless institution purchases or leases

Demonstration Product:

- Unsterilized single-use products, or mockups
- Used for patient awareness, education, and training
- Must <u>not</u> be used in patient care
- Labeled as "Sample," "Not for Human Use," or other suitable designation (on product, packaging, and accompanying

documentation)





Agenda






Addressing Direct Sponsorships in China

- Status of sponsorships under Chinese law is unclear
 - Various anti-bribery & competition laws
 - Prohibitions on what health care organizations and professionals can accept
 - Recently issued rules on donations call sponsorships into question
- Recent enforcement highlights sponsorships allegedly used as bribes or expenses falsely recorded as "sponsorship fees" to disguise bribes
- Some biotech companies have **voluntarily phased out** direct sponsorships
- **Global Trend** direct sponsorship not permitted in the U.S. and being phased out by MedTech Europe and APACMed (both effective 1 Jan. 2018); other geographies do not permit direct sponsorship





Phasing Out Direct Sponsorships



Orange = Direct Sponsorship Phase-Out effective 1 Jan. 2018



Addressing Direct Sponsorships in China – Phase Out

Accordingly, **AdvaMed member companies** plan to phase out direct sponsorship of HCPs to attend third-party educational events, **effective 1 Jan. 2018**

- No direct travel, lodging, meals, or registration fees for individual HCPs to attend third-party educational conferences
- Rather, companies can provide educational grants/donations to conference organizers (or other legitimate grant/donation recipients) to support third-party educational conferences
- Educational grant/donation recipient and/or conference organizer can use grant funds to defray or underwrite HCP costs

Companies can also provide:

- Company-conducted product training and educational meetings;
- Company-conducted satellite symposia in connection with third-party educational conferences; and
- Direct support for HCPs' attendance at technical procedure training courses

These changes are intended to help avoid even the appearance of impropriety and ensure transparency of relationships between companies and HCPs in China





THANK YOU!!



